Twist Bioscience (TWST) director Chan Nelson granted 5,095 shares

Rhea-AI Filing Summary

Twist Bioscience director Chan Nelson received an annual equity award of 5,095 shares of common stock on February 5, 2026. The award was granted at no cash cost per share and increased Nelson’s directly held stake to 33,251 shares.

The shares vest 100% on the earlier of the one-year anniversary of the grant date or the first annual stockholders’ meeting after the grant, as long as Nelson continues serving as a non-employee director on the applicable vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chan Nelson

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,095	$0.00	--

Holdings After Transaction: Common Stock — 33,251 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Nelson

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		A		5,095(1)	A	$0	33,251	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Twist Bioscience (TWST) director Chan Nelson report in this Form 4?

Chan Nelson reported receiving an annual equity award of 5,095 shares of Twist Bioscience common stock. These new shares were granted at $0 per share and increased Nelson’s directly owned holdings to 33,251 shares after the transaction.

When was Chan Nelson’s Twist Bioscience (TWST) equity award granted?

The equity award to Chan Nelson was granted on February 5, 2026. This date is the transaction date reported, and it starts the vesting schedule for the 5,095 shares of Twist Bioscience common stock included in the annual equity award.

How many Twist Bioscience (TWST) shares does Chan Nelson own after this award?

After the reported equity award, Chan Nelson beneficially owns 33,251 shares of Twist Bioscience common stock. This total reflects the addition of 5,095 new shares from the annual equity award to Nelson’s existing directly held position.

What are the vesting terms of Chan Nelson’s Twist Bioscience (TWST) annual equity award?

The 5,095 award shares vest 100% on the earlier of the one-year anniversary of the grant date or the first annual stockholders’ meeting thereafter. Vesting requires that Nelson remains a Non-Employee Director and service provider on the applicable vesting date.

Did Chan Nelson pay cash for the new Twist Bioscience (TWST) shares?

No cash was paid for the new shares; the Form 4 lists a $0 price per share. The 5,095 shares were granted as part of an annual equity award for board service, rather than purchased in an open-market or private cash transaction.

Is Chan Nelson’s Twist Bioscience (TWST) ownership direct or indirect after this transaction?

The filing shows Chan Nelson’s ownership as direct (D) following the transaction. After receiving the 5,095-share equity award, Nelson directly holds a total of 33,251 shares of Twist Bioscience common stock according to the reported data.